Eli Lilly is leading a push with other pharmaceutical companies to request a pause in the Biden administration's drug pricing negotiations, even as officials prepare to release a new list of medications to be targeted for price reductions, Bloomberg reported…

The Federal Trade Commission released a second interim report showing that the three largest pharmacy benefit managers — CVS Caremark, Cigna's Express Scripts and UnitedHealth's Optum Rx — marked up specialty generic drug prices, generating over $7.3 billion in excessive…

AbbVie will write off  $3.5 billion related to its $8.7 billion investment in Cerevel Therapeutics following the failure of the company's key schizophrenia drug, emraclidine, The Wall Street Journal reported Jan. 10. 

Eli Lilly expects its experimental weight loss pill, orforglipron, to receive approval as early as next year, CEO David Ricks told Bloomberg Jan. 13.

The FDA is set to consider approval of an alternative to opioids developed by Vertex Pharmaceuticals, The Washington Post reported Jan. 13. 

Johnson & Johnson is set to acquire Intra-Cellular Therapies for $14.6 billion. 

The prices of the 25 most expensive brand-name drugs covered by Medicare Part D have nearly doubled, rising by an average of 98% since they entered the market, according to a new analysis by the AARP Public Policy Institute. 

Health systems are working to streamline operations by centralizing all medication processes in one location: central pharmacy service centers.

A new report from the Office of the U.S. Trade Representative found that of the 35,000 online pharmacies worldwide, 96% are operating illegally, contributing to the growth of counterfeit medicines. 

GoodRx is monitoring seven potential FDA drug approvals in 2025, including a possible expanded label for Ozempic.